# Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study

> **NCT02239393** · PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 31 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT02239393
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239393, "Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02239393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*